Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).

White CR, Datta G, Mochon P, Zhang Z, Kelly O, Curcio C, Parks D, Palgunachari M, Handattu S, Gupta H, Garber DW, Anantharamaiah GM.

Vasc Dis Prev. 2009 Jan 1;6:122-130.


Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.

Sherman CB, Peterson SJ, Frishman WH.

Cardiol Rev. 2010 May-Jun;18(3):141-7. doi: 10.1097/CRD.0b013e3181c4b508. Review.


Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.

Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM.

Curr Opin Lipidol. 2004 Dec;15(6):645-9. Review.


Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.

Wool GD, Reardon CA, Getz GS.

J Lipid Res. 2008 Jun;49(6):1268-83. doi: 10.1194/jlr.M700552-JLR200. Epub 2008 Mar 5.


Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

White CR, Garber DW, Anantharamaiah GM.

J Lipid Res. 2014 Oct;55(10):2007-21. doi: 10.1194/jlr.R051367. Epub 2014 Aug 25. Review.


Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet.

Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, Signorino P, Densmore JC, Kaul S, Oldham KT, Pritchard KA Jr.

Circ Res. 2005 Nov 25;97(11):1190-7. Epub 2005 Oct 13.


The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease.

Meyer P, Nigam A, Marcil M, Tardif JC.

Curr Atheroscler Rep. 2009 Sep;11(5):329-33. Review.


The effect of HDL mimetic peptide 4F on PON1.

Vakili L, Hama S, Kim JB, Tien D, Safarpoor S, Ly N, Vakili G, Hough G, Navab M.

Adv Exp Med Biol. 2010;660:167-72. doi: 10.1007/978-1-60761-350-3_15. Review.


Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis.

Getz GS, Reardon CA.

J Inflamm Res. 2011;4:83-92. doi: 10.2147/JIR.S12983. Epub 2011 Jun 2.


Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.

Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM.

Circulation. 2004 Jun 29;109(25):3215-20. Epub 2004 Jun 14.


The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit.

Di Bartolo BA, Vanags LZ, Tan JT, Bao S, Rye KA, Barter PJ, Bursill CA.

Lipids Health Dis. 2011 Nov 30;10:224. doi: 10.1186/1476-511X-10-224.


Potential clinical utility of high-density lipoprotein-mimetic peptides.

Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM.

Curr Opin Lipidol. 2006 Aug;17(4):440-4. Review.


Apolipoprotein A-I mimetic peptides.

Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM.

Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1325-31. Epub 2005 Apr 14. Review.


Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.

Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, Vila L, Ordóñez-Llanos J, Blanco-Vaca F.

Circ Res. 2004 Oct 15;95(8):789-97. Epub 2004 Sep 23.


Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.

Anantharamaiah GM, Mishra VK, Garber DW, Datta G, Handattu SP, Palgunachari MN, Chaddha M, Navab M, Reddy ST, Segrest JP, Fogelman AM.

J Lipid Res. 2007 Sep;48(9):1915-23. Epub 2007 Jun 14. Review.


Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.

Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH, Rader DJ.

Circ Res. 2005 Oct 14;97(8):763-71. Epub 2005 Sep 8.


Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.

Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, Kwon M, Ganapathy E, Meriwether D, Farias-Eisner R, Fogelman AM, Reddy ST.

Circ J. 2011;75(7):1533-8. Epub 2011 May 28. Review.


ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose.

Carballo-Jane E, Chen Z, O'Neill E, Wang J, Burton C, Chang CH, Chen X, Eveland S, Frantz-Wattley B, Gagen K, Hubbard B, Ichetovkin M, Luell S, Meurer R, Song X, Strack A, Langella A, Cianetti S, Rech F, Capitò E, Bufali S, Veneziano M, Verdirame M, Bonelli F, Monteagudo E, Pessi A, Ingenito R, Bianchi E.

Bioorg Med Chem. 2010 Dec 15;18(24):8669-78. doi: 10.1016/j.bmc.2010.09.074. Epub 2010 Nov 4.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk